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Abstract: Nanotechnology is the application of nanotechnology within medicine. An illustration 
of this is the use of pegylation as a means of modifying naturally occurring proteins which may 
have clinical applications, in order to improve the pharmacodynamics of the protein resulting in 
an effective medication. An example of this is pegylated interferon. The purpose of this review 
is to examine the chemistry, clinical pharmacology, pharmacokinetics, pharmacodynamics, and 
clinical studies with 40 kDa pegylated interferon to illustrate the general principles of pegylated 
biological proteins. The use in clinical practice is reviewed along with the evidence for both 
efﬁ  ciacy, safety, and advantages over standard interferon. 
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Introduction
Nanostructures measure between 1 and 100 nm and because of their size confer novel 
properties. These have applications in disease diagnosis, treatment, and prevention. 
Nanomedicine is deﬁ  ned as the application of nanotechnology within medicine, that 
is, the monitoring, repair, construction, and control of human biological systems at the 
molecular level using nanodevices and nanostructures. Nanoparticles and nanocap-
sules may be effective delivery systems for drug and gene therapy, and can alter the 
distribution of drugs and other therapeutic agents within the patient’s body (Bogunia-
Kubik and Sugisaka 2002; Editorial 2004). Until now nanotechnology has been used 
to modify existing drugs to improve their pharmacokinetic properties.
Pegylated modiﬁ  cation of interferon alpha
Once administered, protein drugs such as interferon alpha are susceptible to enzyme 
degradation and rapid clearance. In order to be effective they need to be administered 
frequently to provide consistent serum concentrations within the therapeutic range. This 
frequent dosing is both inconvenient for patients and can lead to wide ﬂ  uctuations in 
blood levels. This may reduce efﬁ  cacy and potentially lead to an increase in adverse 
reactions caused by intermittent high peak concentrations (Reddy et al 2002).
Attaching a large inert molecule to a protein is a well-established method for 
decreasing the protein’s clearance. Since the late 1970s, the molecule of choice for 
this process has been polyethylene glycol (PEG). When interferon, a biologically 
active antiviral agent is combined with PEG (“pegylated”), its half-life is increased 
and the rate of drug clearance is decreased. Biological activity is maintained (Reddy 
et al 2002).
The purpose of this review is to examine pegylation as an example of a clinical 
application of nanotechnology and nanomedicine. Here we look at the chemistry, 
clinical pharmacology, pharmacodynamics and clinical studies with the 40 kDa International Journal of Nanomedicine 2007:2(1) 20
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pegylated interferon (peginterferon) alpha-2a, to illustrate 
the general principles of pegylated biological proteins. Other 
long-acting type 1 interferons have been created and one 
other peginterferon (12 kDa pegylated alpha-2b) is currently 
licensed for clinical use. It is not the purpose of this review 
to examine the similarities and differences between these 
two drugs and we will therefore restrict our discussion to the 
40 kDa peginterferon alpha-2a.
Chemistry and potential advantages 
of pegylation
The molecular weight of the PEG moiety, its structure, the 
number and location of peg moieties attached to the protein, 
and the chemical method of attachment determine the physi-
cochemical and pharmacological properties of the resulting 
protein conjugate. For a circulating pegylated protein, the 
optimum mass of a PEG molecule required to prolong renal 
and cellular clearance of molecules is estimated to be 40–60 kDa 
for once-weekly dosing (Yamaoka et al 1994; Fung et al 1997; 
Heathcote et al 1999). Smaller pegylated proteins are ﬁ  ltered 
freely in the glomerulus (Delgado et al 1992; Yamaoka 
et al 1994), and therefore extend protein half-life to a lesser 
extent. However, the optimum size of the PEG molecule 
needed to extend a protein half-life cannot be derived from 
mathematical models and needs to be determined empirically. 
This is because the overall half-life of a pegylated protein is 
determined by a complex variety of factors including absorp-
tion from injection sites and tissue distribution.
PEG chains may be attached at a single or multiple sites 
on the protein molecule. It is preferable for there to be a 
single attachment site as excessive pegylation will decrease 
the activity of the drug (Fung et al 1997; Olsen et al 1997). 
Excessive pegylation will also produce a protein with many 
positional isomers that may have different biological proper-
ties. There are various methods available to join the mono-
functional PEG chains (ie, those with a single attachment site) 
to proteins. Most involve coupling the PEG molecule either 
to amines located on the N-terminus or to lysine residues on 
the protein. These form stable covalant bonds. Alternatively, 
PEG derivatives can be synthesized that are reactive towards 
other nucleophiles on the protein such as sulfhydryl groups. 
The PEG molecule can be stably conjugated to the protein or 
coupled with a hydrolyzable bond that allows slow release 
of the active interferon moiety (Reddy et al 2002).
In the development of the 40 kDa peginterferon alpha-2a, 
studies in rats initially tested a wide range of PEG moieties 
for attachment to interferon alpha-2a (Fung 1997). These 
studies showed that conjugates of interferon alpha-2a with 
PEGs of various molecular weights and structures improved 
the absorption, distribution, and elimination characteristics 
of the protein (Bailon et al 1999,  2001). Different PEG 
conjugates exhibited marked differences in pharmacoki-
netic properties. Peginterferon alpha-2a (40 kDa) conferred 
enhanced pharmacological properties of standard interferon 
alpha-2a in terms of antiviral activity, terminal half-life, and 
mean plasma residence time. Administration of 40 kDa 
peginterferon alpha-2a produced sustained plasma concen-
trations compared with standard interferon alpha-2a (Bailon 
et al 2001). An additional beneﬁ  t of the pegylated molecule 
was a reduction in immunogenicity (Figure 1). That is, standard 
interferon alpha-2a elicited immunogenic responses in mice 
whereas pegylated molecules were less immunogenic. Smaller 
PEG interferons (such as 5 kDa linear peginterferon alpha-2a) 
have reduced immunogenicity and 40 kDa peginterferon 
alpha-2a has been shown not to elicit an antibody response 
(Bailon et al 2001).
Kinetics of 40 kDa peginterferon 
alpha-2a
Two studies have examined the pharmacokinetic properties 
of single dose sub-cutaneous 40 kDa peginterferon alpha-2a 
in healthy volunteers. 
In a study by Xu and colleagues, subjects were adminis-
tered either interferon alpha-2a (3 million international units, 
MIU) or 40 kDa peginterferon alpha-2a (45 μg, 135 μg, or 
270 μg), followed by administration of interferon alpha-2a 
(18 MIU) (Xu et al 1998). The pharmacokinetics of pegin-
terferon alpha-2a (40 kDa) were linear in this dose range. In 
comparison with standard interferon alpha-2a, the pegylated 
form had sustained absorption, reduced systemic clearance, 
and increased serum half-life. 
Similar pharmacokinetic results were reported by Aligranati 
and collegues, who assessed subcutaneous administration of 40 
kDa peginterferon alpha-2a (180 μg) in 20 healthy volunteers. 
Substantial serum levels of 40 kDa peginterferon alpha-2a 
were reached 3–8 hours after dosing and the maximal 
serum concentration of the drug was reached about 80 
hours post injection, reﬂ  ecting the sustained absorption of 
the drug. The mean absorption time was markedly sustained 
for 40 kDa peginterferon alpha-2a compared with published 
data for interferon, indicating that sustained concentrations of 
peginterferon would be present throughout a 1-week dosing 
interval. This was assuming a ﬁ  rst-order absorption process 
(Algranati et al 1999).International Journal of Nanomedicine 2007:2(1) 21
Pegylated interferon alpha-2a for hepatitis C
During multiple dosing in chronic hepatitis C patients 
treated once weekly over 48 weeks, 40 kDa peginterferon 
alpha-2a had sustained absorption and reduced apparent 
total body clearance (Modi et al 2000). During steady state 
concentrations, reached after 5–8 weeks of treatment, the 
peak to trough ratio of 40 kDa peginterferon alpha-2a was 
constant, indicating a uniform concentration throughout 
the dosing interval (Modi et al 2000). The pharmacokinetic 
properties are similar both in healthy volunteers and in 
patients with and without cirrhosis (Heathcote et al 1999).
In summary, clinical studies in both healthy volunteers 
and patients with a variety of different stages of liver disease 
have shown similar results to the initial animal studies 
and indicate that pegylated interferons have enhanced 
pharmacokinetic properties. 
Antiviral activity
The value of enhanced pharmacokinetic properties needs to 
be shown in clinical studies of efﬁ  ciacy. In patients receiving 
treatment for chronic hepatitis C infection (HCV), the response 
to therapy is usually analyzed by determining the proportion 
of patients who have no detectable virus in their circulation 6 
months after completing therapy. This is known as sustained 
virological response (SVR). Long term follow up studies have 
shown that patients who achieve an SVR have an extremely 
low probability of relapse and are probably cured. It is now 
well established that different strains of HCV (known as 
genotypes) respond differently to therapy – patients infected 
with genotype type 1 HCV have much reduced response rates 
compared with patients infected with genotypes 2 and 3. It is 
now recognized that combining ribavarin with interferon-based 
treatment regimes signiﬁ  cantly increases the number of patients 
who achieve a sustained virological response. The results 
from various clinical trials demonstrate that treatment with 
40 kDa peginterferon alpha-2a provides signiﬁ  cant improve-
ment over standard interferon alpha-2a therapy. 
Efﬁ  cacy alone and in combination 
with ribavarin
It has been shown that combination therapy in the form of 
interferon and ribavarin markedly improves therapy results 
compared with monotherapy with interferon alone (Friedrich-
Rust et al 2005) The development of peginterferon has led to 
a further improvement of virological response rates especially 
for genotype 1-infected patients. Results from both phase 2 
and phase 3 trials have shown once weekly administration of 
40 kDa peginterferon alpha-2a to be more effective than three 
times a week administration of standard interferon alpha-2a 
(Zeuzem et al 2000; Reddy et al 2001). 
This result has been shown to be the case in all genotype 
cohorts of hepatitis C patients. Patients with genotype non-1 
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Figure 1 Mean serum activity of standard IFN alpha-2a (▲)and 40 kDa peginterferon alpha-2a (•) after subcutaneous administration in rats. Reprinted with permission 
from Bailon P, Palleroni A, Schaffer CA, et al. 2001. Rational design of a potent long lasting form of interferon: a 40 kDa branched polyethylene glycol conjugated interferon 
alpha-2a for the treatment of hepatitis C. Bioconj Chem, 12:195–202. Copyright © 2001 American Chemical Society.International Journal of Nanomedicine 2007:2(1) 22
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been shown in genotype 1 treated with pegylated interferon. 
Genotype 4 usually exhibits a poorer response to treatment 
than other genotypes, in trials using pegylated interferon the 
response rates have been better (Sherman et al 2000).
In the case of patients with bridging fibrosis and 
cirrhosis, which are notoriously difﬁ  cult to treat, pegylated 
interferon has shown better outcomes in terms of virological, 
biochemical, and histological responses. Meta-analysis of all 
peginterferon alpha-2a monotherapy trials conﬁ  rms that the 
response rates to 40 kDa peginterferon alpha-2a are much 
higher than to standard interferon alpha-2a both in patients 
with difﬁ  cult-to-treat disease because of genotype or with 
complications such as cirrhosis (Pockros et al 2000).
In combination with ribavarin, peginterferon alpha-2a 
has been shown to be superior to peginterferon alone and 
standard interferon alpha-2b plus ribavarin, in interferon-
naive patients (Fried et al 2001). In a large randomized 
control trial involving two thirds patients with genotype 1 
infection, patients treated with both 40 kDa peginterferon 
alpha-2a and ribavarin had better virological responses than 
other treatment regimes (Fried et al 2001).  
Tolerability
Several studies have compared peginterferon with standard 
interferon in patients with hepatitis C, both with and without 
complications such as ﬁ  brosis and cirrhosis. In these studies 
peginterferon alpha-2a has been shown to be tolerated as well 
as if not better than standard interferon alpha-2a (Heathcote 
et al 2000; Zeuzem et al 2000; Reddy et al 2001) The 
frequency of adverse events are also reported as similar with 
peginterferon and standard therapy interferon alpha-2a. 
Side-effects reported with peginterferon are typical of 
those reported for interferon therapy and include: depression, 
pyrexia, rigors, nausea, vomiting, impaired concentration, 
and alopecia (Zeuzem et al 2000; Reddy et al 2001). 
Psychiatric events such as severe depression, psychosis, and 
personality disorder have been reported as similar in patients 
taking standard interferon and peginterferon (Heathcote et al 
2000; Zeuzem et al 2000) In the general chronic hepatitis C 
population similar ﬁ  ndings have been reported. 
Another well-established group of adverse effects 
of interferon treatment are hematological abnormalities, 
particularly in those patients with cirrhosis. In studies com-
paring standard interferon with peginterferon, the incidence 
of neutropenia is reported as similar (Heathcote et al 2000; 
Zeuzem et al 2000) Thrombocytopenia, although uncommon, 
has been reported as higher in one study in those patients with 
cirrhosis treated with 40 kDa peginterferon alpha-2a rather 
than those treated with standard interferon alpha-2a. In the 
same study the patients with chronic hepatitis C and not 
cirrhosis had similar rates of thrombocytopenia (Heathcote 
et al 2000). Anemia has been reported with both therapies 
and in one study one patients the discontinuation of therapy 
with peginterferon due to anemia (Zeuzem et al 2000). 
Using quality of life questionnaires, results have been better 
in patients treated with 40 kDa peginterferon alpha-2a compared 
with standard interferon alpha-2a. An analysis of patients partici-
pating in a randomized control trial revealed that those receiving 
40 kDa peginterferon alpha-2a experienced signiﬁ  cantly better 
quality of life and less fatigue than those treated with standard 
interferon alpha-2a as early as 2 weeks into therapy with the 
differences persisting at 12 weeks (Rasenack et al 2000). At 
this time signiﬁ  cantly more patients treated with peginterferon 
alpha-2a rated themselves as feeling “better or much better” than 
1 year earlier. Similar results have been reported for patients 
with cirrhosis (Cooksley et al 2000).
Based on these results, it is clear that patients with hepatitis 
C with and without cirrhosis may safely be treated with pegin-
terferon alpha-2a. By adding the PEG molecules to interferon 
additional adverse events are not experienced, and quality of life 
is generally better in those treated with pegylated interferon. 
Disadvantages of peginterferon
The addition of PEG moieties to type I interferon 
has significantly enhanced the pharmacokinetic and 
pharmacodynamic properties of the molecule. However 
production of peginterferon is not a trivial process and has 
required substantial investment in manufacturing technology 
which has resulted in a substantial increase in production 
costs. Furthermore the peginterferon is less active on a mole 
for mole basis when compared with unmodiﬁ  ed interferon. 
In the clinic this problem is easily overcome by using 
larger quantities of drug, but the use of large amounts of an 
expensively produced therapeutic inevitably signiﬁ  cantly 
increases unit costs. Thus the chief disadvantage of the 
peginterferon is the unavoidable increase in drug prices 
leading to a signiﬁ  cant increase in drug costs. Although the 
use of the more expensive peginteferons is cost effective 
there is a net increase in health care expenditure that is 
burdensome to many. 
Health economic data
The value of any new technology needs to be assessed in both 
clinical and economic terms and pegylated interferon has been International Journal of Nanomedicine 2007:2(1) 23
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assessed in this way. A 10-year projection from 1998 estimates 
that increases in chronic hepatitis C related diseases will 
occur as follows: cirrhosis (61%), decompensated cirrhosis 
(279%), hepatocellular carcinoma (68%), liver transplantation 
(528%), and liver-related deaths (223%) (Davis et al 1998). 
Approximately 170 million people worldwide are infected 
with hepatitis C (WHO 1999). Approximately 100 000 new 
cases occur every year in the United States (CDC 1998; EASL 
1999; Alter et al 1999). Presently hepatitis C-related liver 
disease accounts for 8000 to 10 000 deaths per year in the 
United States (CDC 1998). Patients with develop hepatitis C 
are at risk of serious long-term sequelae including cirrhosis, 
hepatocellular carcinoma, liver transplantation, and death from 
liver disease-related causes.
Health ecomonic models have been used to assess the 
long-term effects and cost effectiveness of peginterferon 
therapy in hepatitis C patients. They have shown that in 
terms of QALY (quality adjusted life years), peginterferon 
alpha-2a is cost effective in the management of hepatitis C 
(Annemans et al 2004).
Conclusion
Standard interferon is absorbed rapidly and then quickly 
eliminated from the body, peak levels occur within hours of 
subcutaneous administration of the drug, and decline rapidly 
to be undetectable at 24 hours. This means patients experience 
sub-therapeutic levels of the drug for the majority of the time. 
Using techniques evolved though nanomedicine, the 
protein interferon has been altered by way of attaching a 
PEG moiety. This adaptation improves the pharmacokinetic 
properties of the protein. This includes increased solubility, 
increased resistance to enzyme degradation, reduced 
immunogenicity, and reduced renal clearance. Peginterferon 
alpha-2a (40 kDa) exhibits sustained absorption, less 
variability in peak and trough concentrations, a restricted 
volume of distribution, and reduced renal clearance compared 
with standard interferon. 
Pegylation results in a drug that can be administered 
once a week producing a sustained virological response 
throughout the whole week. The trials that have been 
performed to compare standard and peginterferon have 
shown better efﬁ  cacy in combination with ribavarin than 
standard interferon. These results are probably due to the 
reasons summarized. Pegylation does not seem to result in 
more adverse events or side-effects than standard interferon 
and patients have reported feeling better while taking 
peginterferon than standard interferon.
Over the next 10 years it is evident that hepatitis C will 
become a global health care problem, inducing end-stage 
liver disease in many millions of individuals. It is therefore 
important in both in clinical and economic terms to establish 
the best possible ways of treating the disease, and preventing 
long-term complications. Combination therapy involving 
interferon and ribavarin have been shown to be effective in 
the treatment of the disease. Peginterferon has advantages 
over standard interferon, and is an effective method of 
administrating interferon. 
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